Cargando…

Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database

Purpose: To identify outpatient treatment patterns of patients with exudative age-related macular degeneration (AMD) who received approved anti–vascular endothelial growth factor (VEGF) therapy, using real-world data from hospitals in Japan. Methods: A hospital claims database was retrospectively re...

Descripción completa

Detalles Bibliográficos
Autores principales: Iida, Tomohiro, Narimatsu, Aya, Adachi, Kenji, Wang, Edward CY
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471391/
https://www.ncbi.nlm.nih.gov/pubmed/37664082
http://dx.doi.org/10.36469/9887
_version_ 1785099840790724608
author Iida, Tomohiro
Narimatsu, Aya
Adachi, Kenji
Wang, Edward CY
author_facet Iida, Tomohiro
Narimatsu, Aya
Adachi, Kenji
Wang, Edward CY
author_sort Iida, Tomohiro
collection PubMed
description Purpose: To identify outpatient treatment patterns of patients with exudative age-related macular degeneration (AMD) who received approved anti–vascular endothelial growth factor (VEGF) therapy, using real-world data from hospitals in Japan. Methods: A hospital claims database was retrospectively reviewed for patients diagnosed with exudative AMD who were treated with anti-VEGF therapy in the outpatient setting between January 2010 and December 2012. Within a treatment period of at least 12 months, the frequency of anti-VEGF injections and AMD-related visits, and time intervals between AMD-related visits and anti-VEGF injections were captured for patients who had neither cataracts nor glaucoma. “Loading dose regimen” was defined as the first 2 or 3 monthly doses and “PRN maintenance regimen” (where PRN=pro re nata) was defined as the entire period of time after the loading doses had been administered. Results: Claims data were collected from a total of 219 patients from 13 of 126 hospitals: 217 treated with ranibizumab (8 received pegaptanib as well), 2 with aflibercept. Of these, 68 patients were treated for at least 12 months (all with ranibizumab PRN), and 29 had neither cataracts nor glaucoma and were included in the treatment pattern analysis. These 29 patients received a mean of 3.8 injections in the first 12 months and another 2.5 injections in the second 12 months of treatment. The average number of all outpatient visits was 16.1 in the first 12 months and 13.7 in the second 12 months, and an average of 11.6 days elapsed between injections and the previous outpatient monitoring visits using a PRN schedule. Conclusion: In a real-world setting in Japan, anti-VEGF PRN injections are administered less frequently than in clinical trials, and with time between monitoring and re-injection visits. Nonetheless, patients still visit the hospital frequently, which can significantly burden patients, caregivers, and healthcare providers.
format Online
Article
Text
id pubmed-10471391
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Columbia Data Analytics, LLC
record_format MEDLINE/PubMed
spelling pubmed-104713912023-09-01 Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database Iida, Tomohiro Narimatsu, Aya Adachi, Kenji Wang, Edward CY J Health Econ Outcomes Res Ophthalmology Purpose: To identify outpatient treatment patterns of patients with exudative age-related macular degeneration (AMD) who received approved anti–vascular endothelial growth factor (VEGF) therapy, using real-world data from hospitals in Japan. Methods: A hospital claims database was retrospectively reviewed for patients diagnosed with exudative AMD who were treated with anti-VEGF therapy in the outpatient setting between January 2010 and December 2012. Within a treatment period of at least 12 months, the frequency of anti-VEGF injections and AMD-related visits, and time intervals between AMD-related visits and anti-VEGF injections were captured for patients who had neither cataracts nor glaucoma. “Loading dose regimen” was defined as the first 2 or 3 monthly doses and “PRN maintenance regimen” (where PRN=pro re nata) was defined as the entire period of time after the loading doses had been administered. Results: Claims data were collected from a total of 219 patients from 13 of 126 hospitals: 217 treated with ranibizumab (8 received pegaptanib as well), 2 with aflibercept. Of these, 68 patients were treated for at least 12 months (all with ranibizumab PRN), and 29 had neither cataracts nor glaucoma and were included in the treatment pattern analysis. These 29 patients received a mean of 3.8 injections in the first 12 months and another 2.5 injections in the second 12 months of treatment. The average number of all outpatient visits was 16.1 in the first 12 months and 13.7 in the second 12 months, and an average of 11.6 days elapsed between injections and the previous outpatient monitoring visits using a PRN schedule. Conclusion: In a real-world setting in Japan, anti-VEGF PRN injections are administered less frequently than in clinical trials, and with time between monitoring and re-injection visits. Nonetheless, patients still visit the hospital frequently, which can significantly burden patients, caregivers, and healthcare providers. Columbia Data Analytics, LLC 2014-07-08 /pmc/articles/PMC10471391/ /pubmed/37664082 http://dx.doi.org/10.36469/9887 Text en https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Ophthalmology
Iida, Tomohiro
Narimatsu, Aya
Adachi, Kenji
Wang, Edward CY
Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database
title Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database
title_full Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database
title_fullStr Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database
title_full_unstemmed Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database
title_short Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database
title_sort anti-vascular endothelial growth factor outpatient treatment patterns in patients with exudative age-related macular degeneration from a japanese hospital claims database
topic Ophthalmology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471391/
https://www.ncbi.nlm.nih.gov/pubmed/37664082
http://dx.doi.org/10.36469/9887
work_keys_str_mv AT iidatomohiro antivascularendothelialgrowthfactoroutpatienttreatmentpatternsinpatientswithexudativeagerelatedmaculardegenerationfromajapanesehospitalclaimsdatabase
AT narimatsuaya antivascularendothelialgrowthfactoroutpatienttreatmentpatternsinpatientswithexudativeagerelatedmaculardegenerationfromajapanesehospitalclaimsdatabase
AT adachikenji antivascularendothelialgrowthfactoroutpatienttreatmentpatternsinpatientswithexudativeagerelatedmaculardegenerationfromajapanesehospitalclaimsdatabase
AT wangedwardcy antivascularendothelialgrowthfactoroutpatienttreatmentpatternsinpatientswithexudativeagerelatedmaculardegenerationfromajapanesehospitalclaimsdatabase